Orchid Pharma Limited (IN:ORCHPHARMA)
:ORCHPHARMA
Want to see IN:ORCHPHARMA full AI Analyst Report?
Top Page
Orchid Pharma Limited
(ORCHPHARMA)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹641.00
▼(-19.36% Downside)
Action:Reiterated
Date:03/05/26
The score is supported by improving profitability and a strong, low-leverage balance sheet, but is meaningfully reduced by negative free cash flow and weak cash conversion. Technicals are bearish with the stock trading below major moving averages and negative MACD, and valuation is pressured by an extremely high P/E with no dividend yield data.
Positive Factors
Strong balance sheet / low leverage
A high equity ratio and very low debt-to-equity provide lasting financial resilience. This structure reduces refinancing and interest-rate risk, preserves strategic optionality for capex or regulatory spending, and supports operations across market cycles without reliance on external debt.
Negative Factors
Negative free cash flow and declining FCF
Negative and declining free cash flow constrains the firm's ability to fund capex, working capital, and regulatory filings internally. Over months this may force external financing, delay product launches, or limit capacity expansion, reducing strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
A high equity ratio and very low debt-to-equity provide lasting financial resilience. This structure reduces refinancing and interest-rate risk, preserves strategic optionality for capex or regulatory spending, and supports operations across market cycles without reliance on external debt.
Read all positive factors
Orchid Pharma Limited (ORCHPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹36.37B
Dividend YieldN/A
Average Volume (3M)10.21K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue Growth-10.02%
EPS Growth-82.90%
CountryIN
Employees871
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)10.31
Shares Outstanding50,719,105
10 Day Avg. Volume2,303
30 Day Avg. Volume10,213
Financial Highlights & Ratios
PEG Ratio12.87
Price to Book (P/B)3.13
Price to Sales (P/S)4.31
P/FCF Ratio-30.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)18
Revenue Forecast (FY)₹15.13B
Orchid Pharma Limited Business Overview & Revenue Model
Company Description
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingred...
How the Company Makes Money
null...
Orchid Pharma Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
72
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.21B | 9.22B | 8.19B | 6.66B | 5.60B | 4.50B |
| Gross Profit | 3.27B | 3.55B | 1.36B | 706.89M | 2.32B | 2.09B |
| EBITDA | 1.02B | 1.45B | 1.42B | 1.43B | 621.38M | 650.03M |
| Net Income | 522.57M | 996.57M | 921.66M | 463.18M | -19.51M | -1.17B |
Balance Sheet | ||||||
| Total Assets | 17.22B | 16.88B | 15.54B | 12.25B | 11.11B | 12.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.50B | 1.83B | 45.24M | 275.21M | 48.27M | 315.15M |
| Total Debt | 2.82B | 1.75B | 1.35B | 3.31B | 2.68B | 4.53B |
| Total Liabilities | 4.48B | 4.21B | 3.84B | 5.37B | 4.63B | 5.84B |
| Stockholders Equity | 12.74B | 12.67B | 11.69B | 6.89B | 6.47B | 6.53B |
Cash Flow | ||||||
| Free Cash Flow | -1.47B | -1.31B | 611.77M | -665.75M | 780.71M | 229.82M |
| Operating Cash Flow | 115.10M | 192.15M | 1.26B | 183.38M | 924.75M | 235.86M |
| Investing Cash Flow | -906.39M | -269.31M | -3.12B | -312.14M | 1.13B | 672.05M |
| Financing Cash Flow | 1.00B | 252.22M | 1.67B | 311.66M | -2.17B | -1.65B |
Orchid Pharma Limited Technical Analysis
Positive
794.90
Price Trends
576.65
Positive
643.92
Positive
706.05
Positive
Market Momentum
42.94
Negative
74.79
Negative
88.78
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORCHPHARMA, the sentiment is Positive. The current price of 794.9 is above the 20-day moving average (MA) of 647.77, above the 50-day MA of 576.65, and above the 200-day MA of 706.05, indicating a bullish trend. The MACD of 42.94 indicates Negative momentum. The RSI at 74.79 is Negative, neither overbought nor oversold. The STOCH value of 88.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ORCHPHARMA.
Orchid Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹30.73B | 18.57 | ― | 0.28% | 7.19% | 82.31% | |
61 Neutral | ₹26.43B | 2.94 | ― | ― | 18.18% | ― | |
60 Neutral | ₹35.09B | 29.38 | ― | 0.97% | 8.37% | 19.15% | |
57 Neutral | ₹28.55B | 67.80 | ― | 0.03% | 9.88% | -40.57% | |
54 Neutral | ₹36.37B | -76.20 | ― | ― | -10.02% | -82.90% | |
53 Neutral | ₹27.69B | -253.30 | ― | ― | 6.64% | -177.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ORCHPHARMA
Orchid Pharma Limited
717.15
-24.25
-3.27%
IN:BLISSGVS
Bliss Gvs Pharma Limited
290.50
169.80
140.68%
IN:GUFICBIO
Gufic Biosciences Limited
284.70
-90.70
-24.16%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
119.54
34.47
40.52%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
574.75
95.85
20.01%
IN:UNICHEMLAB
Unichem Laboratories Limited
375.35
-233.85
-38.39%
Orchid Pharma Limited Corporate Events
Orchid Pharma says NCLT dismisses DBS Bank lease rent claim with no impact on operations
Apr 11, 2026
Orchid Pharma has disclosed that the National Company Law Tribunal’s Chennai Bench has dismissed an application filed by DBS Bank, formerly Lakshmi Vilas Bank, seeking lease rent and insolvency resolution process costs for the period when th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.